MindMaze Therapeutics to Present at Upcoming Investor and Industry Conferences

MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced its participation in several upcoming investor and industry conferences in the United States and Europe. Investor Conferences Conference: Baader Investment Conference Location: Munich, Germany Presentation: September 21, 2026 at 5:40 p.m. CET Conference: Global Markets Forum Location: New York, NY Presentation: October 7, 2026 Management will be available for one-on-one meetings. Investors interested in meeting with the Company are invited to contact [email protected] . Industry Conferences Conference: American Medical Rehabilitation Providers Association (AMRPA) Educational Conference Location: Austin, TX Presentation: September 27–30, 2026 Conference: American Congress of Rehabilitation Medicine (ACRM) Annual Fall Conference Location: Washington, DC Presentation: October 13–15, 2026 Conference: American Academy of Physical Medicine and Rehabilitation (AAPM&R) 2026 Annual Assembly Location: Orlando, FL Presentation: November 11–14, 2026 Conference: HLTH USA 2026 Location: Las Vegas, NV Presentation: November 17, 2026 at 3:30 p.m. PST At these industry conferences, MindMaze Therapeutics will exhibit its neurotechnology solutions and present its growing body of real-world evidence, highlighting the potential of its solutions to improve the delivery of neurorehabilitation across the continuum of care. Relevant presentation materials and replays, where available, will be posted on the Company's website. About MindMaze Therapeutics MindMaze Therapeutics (SIX: MMTX ) is a global leader in scalable, precision neurotherapeutics, dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. The company's FDA-listed and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson's disease, and other neurological disorders. With an extensive library of rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine. For more information, visit www.mindmazetherapeutics.com . Media & Investor Contacts Jeremy Meinen, Chief Financial Officer [email protected]